Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9573 posts found.

1920px-hiv-budding-color

KCL study could lead to improved vaccinations against STIs

May 23, 2019 Research and Development HIV, HSV, STIs, herpes, immune system, std

New findings from researchers at King’s College London could lead to improved vaccinations against sexually transmitted infections (STIs). Researchers at …
News

Array Biopharma’s Braftovi triple therapy meets both endpoints in advanced colorectal cancer subtype

May 22, 2019 Research and Development Array Biopharma, Braftovi, Cancer, colorectal cancer, pharma

Array Biopharma has revealed new data on its combination of Braftovi (encorafenib), Mektovi (binimetinib), and Erbitux (cetuximab), showing that it …
News
amgen_flag

Amgen agrees to buy Nuevolution for $167 million

May 22, 2019 Research and Development Amgen, Cancer, Nuevolution, biotech, drug discovery, immuno-oncology, immunology, pharma

California biotech Amgen has agreed to buy Danish biopharmaceutical company Nuevolution AB for 1.61 billion Swedish crowns ($166.8 million). The …
News
takeda_global_hq

Takeda scores Japanese Entyvio approval in Crohn’s disease

May 22, 2019 Research and Development, Sales and Marketing Crohn’s disease, Entyvio, Japan, crohn's disease, pharma

Takeda has announced that Japan’s drug regulator, the Ministry of Health, Labour and Welfare (MHLW), has approved Entyvio (vedolizumab) in …
News
merckwindow_web

MSD buys Peloton Therapeutics in deal worth $2.1 billion

May 22, 2019 Research and Development Cancer, MSD, acquisition, biotech, deal, oncology, pharma

MSD has agreed to acquire all outstanding shares in Peloton Therapeutics in a deal worth up to $2.1 billion. US …
News

Children wait six and half years longer than adults for new cancer drugs, study says

May 22, 2019 Research and Development Cancer, FDA, children, oncology, paediatrics, pharma

Children wait six and half years longer than adults to access new cancer drugs, according to a study from Dana-Farber/Boston …
News
spravato

New Phase 3 data backs up the efficacy of esketamine in treatment-resistant depression

May 21, 2019 Manufacturing and Production, Research and Development, Sales and Marketing Spravato, depression, esketamine, pharma

New research has been published on the efficacy of esketamine in the treatment of depression, following its approval from the …
News

Xenon halts effects of head injuries in mice

May 21, 2019 Manufacturing and Production, Research and Development TBI, brain injury, head injury, pharma, xenon

Researchers at Imperial College London (ICL) and Johannes Gutenberg University Mainz have shown that xenon prevents early death and long-term …
News
merck-keytruda

Keytruda fails to improve overall survival in advanced triple-negative breast cancer

May 21, 2019 Manufacturing and Production, Research and Development Cancer, MSD, breast cancer, keytruda, pharma, triple-negative breast cancer

MSD has made it known that its cancer immunotherapy Keytruda (pembrolizumab) failed to meet its primary endpoint in a Phase …
News
antibiotic-resistance-pill-running-from-bacteria-1500

The global rise in antibiotic resistance threatens infection prevention and cure

May 20, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing antibiotic resistance, antimicrobial resistance, feature, pharma

Dr Bill Love, Founder and Chief Scientific Officer of Destiny Pharma, discusses the rise of antimicrobial resistance (AMR), the antibiotic …
Feature
abbvie_0

AbbVie terminates Phase 3 brain cancer study after Depatux-M shows no benefit

May 20, 2019 Research and Development, Sales and Marketing AbbVie, Cancer, Depatux-M, glioblastoma, pharma, trial failure

AbbVie has terminated a Phase 3 study of the efficacy of Depatux-M (depatuxizumab mafodotin) in the treatment of newly diagnosed …
News
boehringer_biberach_germany_copy

Boehringer’s Pradaxa fails to meet Phase 3 endpoint in preventing recurrent stroke

May 20, 2019 Research and Development, Sales and Marketing Boehringer, Pradaxa, pharma, stroke, trial failure

Boehringer has announced that Pradaxa (dabigatran etexilate mesylate) has failed to meet its primary endpoint in its Phase 3 study, …
News
takeda_usa_pharmaceuticals_u

Takeda’s Entyvio beats Humira for remission in ulcerative colitis, exploratory data show

May 20, 2019 Research and Development, Sales and Marketing AbbVie Humira, Entyvio, Takeda, pharma, ulcerative colitis

Takeda has unveiled exploratory data on its gut-selective biologic drug Entyvio (vedolizumab) at the 2019 Digestive Disease Week, demonstrating its …
News
roche__tree

Phase 1/2 data show Roche’s entrectinib shrinks tumours with NTRK, ROS1 or ALK gene fusions in children & adolescents

May 17, 2019 Medical Communications, Research and Development Cancer, Roche, entrectinib, pharma

Roche has unveiled new Phase 1/2 data for its selective tyrosine kinase inhibitor entrectinib, demonstrating its ability to shrink recurrent …
News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

May 17, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Gilead, J&J, JJ, Janssen, Mundipharma, Novartis, Teva, generics

Some big names – including Gilead, Janssen, Teva and Bristol-Myers Squibb – were in trouble this week after two separate …
News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025